According to a new report, published by KBV research, The Global Hospital-Acquired Infection Diagnostics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 7.8% CAGR during the forecast period.
The Instrument market is witnessing CAGR of 9.6% during (2022 - 2028). With increasing advanced level of infections contracted by the people inside the hospital premise and increasing complexity to diagnose such infections, the need of well-developed instruments with the purpose to accurately diagnose the infections and other diseases would propel in the coming years. More advanced level instruments are being included by several hospitals and healthcare units.
The Urinary Tract Infections (UTI) segment is leading the Global Hospital-Acquired Infection Diagnostics Market by Infection Type in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.6 billion by 2028. It is because of the high prevalence of pneumonia in hospitalized patients. Infections of the urinary tract are more prevalent in women. The most frequent infections affect the bladder or urethra, but more serious infections damage the kidney. Pelvic pain increased urination urges, urination pain, and blood in the urine are all symptoms of a bladder infection. Back discomfort, vomiting, nausea, and fever are all symptoms of a kidney infection.
The Disease Testing segment has shown growth rate of 9.2% during (2022 - 2028). A screening test is performed to detect possible health problems or diseases in people who have no symptoms. The objective is to lower illness risk by timely detection and lifestyle variation or surveillance or to discover the disease early enough to cure it successfully. When the disease is symptom-free, disease testing is really useful for early detection.
The Molecular Diagnostics segment acquired maximum revenue share in the Global Hospital-Acquired Infection Diagnostics Market by Test Type in 2021; thereby, achieving a market value of $2.2 billion by 2028. The detection of genetic variations is referred to as molecular diagnostics, and it aims to make detection, sub-classification, diagnosis, prognosis, and tracking response to medication easier. Molecular diagnostics is the result of beneficial collaboration between genomics knowledge, laboratory medicine, and technology in the area of molecular genetics, particularly with recent breakthroughs in molecular genomic technologies. All of its criteria help to identify and characterize the genetic basis of inherited disorders, which is necessary for appropriate diagnosis.
The Standalone Laboratories segment is showcasing a CAGR of 8.5% during (2022 - 2028). The Stand-Alone Laboratory is a station part that has everything needed to make a fully working space station in a single piece. It has solar panels built to power its onboard batteries (cargo), as well as a rocket engine and internal fuel tanks that can be re-filled.
The North America market dominated the Global Hospital-Acquired Infection Diagnostics Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1.97 billion by 2028. The Europe market is estimated to witness a CAGR of 7.1% during (2022 - 2028). Additionally, The Asia Pacific market would experience a CAGR of 8.5% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/hospital-acquired-infection-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.
By Product
By Infection Type
By Application
By Test Type
By End User
By Geography
Companies Profiled
Unique Offerings 
